ストックスクリーナーアプリを入手
291.25
0.47%
1.2935
前日終値:
$289.96
開ける：
$295.44
24時間の取引高:
432.31K
Relative Volume:
0.45
時価総額：
$37.99B
収益：
$2.35B
当期純損益:
$-269.70M
株価収益率:
-139.36
EPS:
-2.09
ネットキャッシュフロー:
$-75.39M
1週間 パフォーマンス:
-0.13%
1か月 パフォーマンス:
+15.80%
6か月 パフォーマンス:
+14.81%
1年 パフォーマンス:
+97.15%
1日の値動き範囲:
$289.89
$295.44
1週間の範囲:
$284.19
$298.23
52週間の値動き範囲:
$146.79
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
291.32 | 38.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
237.59 | 25.23B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.50 | 113.16B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.26 | 40.65M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.16 | 64.41B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.84 | 6.18B | 0 | -153.72M | -103.81M | -2.00 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam Pharmaceuticals’ SWOT analysis: stock outlook amid Amvuttra launch - Investing.com
Biogen partners with Alnylam founder John Maraganore’s new RNAi startup - The Business Journals
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Alnylam supports LGBT community inside and outside the workplace - The Business Journals
3 High-Flying Stocks That Could Soar Even More - AOL.com
Huntington's Disease Pipeline 2025: Groundbreaking Clinical - openPR.com
Alnylam Issues 2024 Corporate Responsibility Report - BioSpace
Alnylam Issues 2024 Corporate Responsibility Report | ALNY Stock News - GuruFocus
Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - MSN
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at He - GuruFocus
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at Heart Failure 2025 Congress | ALNY Stock News - GuruFocus
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN
Alnylam (ALNY) Reports Positive Long-Term Data for Amvuttra in C - GuruFocus
Alnylam posts new data for heart disease drug (ALNY:NASDAQ) - Seeking Alpha
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire
High Growth US Tech Stocks To Watch In May 2025 - simplywall.st
Cardiac amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com
Promoting A Newly Approved Indication Against Established Competitors - Life Science Leader
Alnylam Halts Patent Row Over Pfizer, BioNTech COVID-19 Vax - Law360
Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now - Reuters
Alnylam shareholders approve executive compensation plan By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term - Yahoo
Alnylam shareholders approve executive compensation plan - Investing.com
Alnylam Pharma Re-elects Directors at Annual Meeting - TipRanks
12 Best Growth Stocks to Buy and Hold for the Long Term - Insider Monkey
Hypercholesterolemia Treatment Market Top Companies Study - openPR.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $319.17 Consensus Target Price from Analysts - Defense World
Alnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure Congress - simplywall.st
Alnylam to present key data on amyloidosis treatments By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability - Yahoo Finance
Alnylam (ALNY) to Unveil Latest Transthyretin Amyloidosis Data a - GuruFocus
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress - marketscreener.com
Alnylam to Share Progress Across its Transthyretin Amyloidosis F - GuruFocus
Alnylam to present key data on amyloidosis treatments - Investing.com Australia
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire
Trend Tracker for (ALNY) - news.stocktradersdaily.com
‘Our bodies are art’: Alnylam campaign uses dance to tell patient’s story - Medical Marketing and Media
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Becker's Hospital Review
RNA Therapy Market Booms Amid Advancements in mRNA and Gene - openPR.com
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Benzinga
LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight - ADVFN
Dysautonomia Market Forecasted to Surge in Coming Years, - openPR.com
Porphyria Treatment Market Grows with Targeted Rare Disease - openPR.com
Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications - Pharma Voice
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to “Buy” at StockNews.com - Defense World
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
Alnylam Pharmaceuticals Inc (ALNY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BONNEY MICHAEL W | Director |
May 15 '25 |
Sale |
277.71 |
11,250 |
3,124,217 |
16,804 |
0.71%
0.64%
大文字化:
|
ボリューム (24 時間):